^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    enitociclib (VIP152)

    i
    Company:
    Bayer, Vincerx
    Drug class:
    CDK9 inhibitor, P-TEFb inhibitor
    Related drugs:
    Apply
    Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies (NCT05371054)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/06/2024
    Initiation :
    04/05/2023
    Primary completion :
    03/10/2025
    Completion :
    03/10/2025
    ALK • BCL2
    |
    MYC rearrangement
    |
    Venclexta (venetoclax) • prednisone • enitociclib (VIP152)
    Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer (VNC-152-101) (NCT02635672)
    Phase 1
    Vincerx Pharma, Inc.
    Active, not recruiting
    Last update posted :
    08/16/2023
    Initiation :
    02/10/2016
    Primary completion :
    12/30/2024
    Completion :
    12/30/2024
    MYC
    |
    MYC amplification • MYC expression
    |
    Keytruda (pembrolizumab) • enitociclib (VIP152)